Jim Simons Vaxcyte, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$34.66 - $54.07 $7.12 Million - $11.1 Million	-205,400 Reduced 48.8%	215,477 $10.8 Million
Q1 2023 May 12, 2023	SELL	$36.27 - $47.2 $3.67 Million - $4.77 Million	-101,100 Reduced 19.37%	420,877 $15.8 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $8.82 Million - $20.6 Million	428,777 Added 460.06%	521,977 $25 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $446,814 - $587,718	20,600 Added 28.37%	93,200 $2.24 Million
Q2 2022 Aug 12, 2022	BUY	$17.68 - $26.58 $562,224 - $845,244	31,800 Added 77.94%	72,600 $1.58 Million
Q1 2022 May 13, 2022	BUY	$17.46 - $26.36 $485,388 - $732,808	27,800 Added 213.85%	40,800 $985,000
Q4 2021 Feb 11, 2022	BUY	$19.32 - $26.45 $251,160 - $343,850	13,000 New	13,000 $309,000

352

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.1B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.